Merck Serono, the pharmaceuticals division of Germany's Merck KGaA, has submitted a supplemental New Drug Application to the Japanese Ministry of Health, Labor and Welfare for a new indication of Gonal-f/Gonalef (follitropin alfa for injection) for ovulation induction in infertile women. The submission is supported by a Phase III single-blinded, controlled study conducted in a Japanese patient population.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze